# A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

> **NCT04758962** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Virus Diseases

## Interventions

- **BIOLOGICAL:** 1 µg CoV2 SAM (LNP)

## Key facts

- **NCT ID:** NCT04758962
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2021-06-04
- **Final completion:** 2022-04-19
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04758962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04758962, "A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04758962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*